vTv Therapeutics

Yahoo Finance • 2 days ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD,... Full story

Yahoo Finance • 8 days ago

vTv Therapeutics registers 15.9M Class A shares for potential resale

* vTv Therapeutics (VTV [https://seekingalpha.com/symbol/VTV]) registered 15.88M Class A common shares for resale by selling stockholders. * Includes 2.13M outstanding shares, plus shares issuable from warrants: 8.47M shares via pre-fu... Full story

Yahoo Finance • 10 days ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • last month

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to i... Full story

Yahoo Finance • 2 months ago

VTV Therapeutics Inc-CL A (NASDAQ:VTVT) Reports Wider Q2 2025 Loss Amid Clinical-Stage Progress

VTV THERAPEUTICS INC-CL A (NASDAQ:VTVT [https://www.chartmill.com/stock/quote/VTVT/profile]) reported its second-quarter 2025 financial results, posting a net loss per share of $0.92, which was wider than the analyst consensus estimate of... Full story

Yahoo Finance • 2 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadersh... Full story

Yahoo Finance • 2 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin b... Full story

Yahoo Finance • 5 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial O... Full story

Yahoo Finance • 5 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc... Full story

Yahoo Finance • 7 months ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief... Full story

Yahoo Finance • 7 months ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months H... Full story

Yahoo Finance • 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story

Yahoo Finance • 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story

Yahoo Finance • 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story

Yahoo Finance • 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin(TTP399) as an adjunctive therapy to insulin for the treatmen... Full story

Yahoo Finance • 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatm... Full story

Yahoo Finance • 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatme... Full story

Yahoo Finance • 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

WESTON, Fla., June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatme... Full story

Yahoo Finance • 3 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Finan... Full story

Yahoo Finance • 3 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced... Full story